244 related articles for article (PubMed ID: 25737303)
21. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
22. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
[TBL] [Abstract][Full Text] [Related]
23. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Chiang NJ; Yen CC; Li CF; Chen LT
Oncotarget; 2014 Nov; 5(22):11723-36. PubMed ID: 25375091
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
25. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
26. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.
Nakatani H; Kobayashi M; Jin T; Taguchi T; Sugimoto T; Nakano T; Hamada S; Araki K
Cancer Sci; 2005 Feb; 96(2):116-9. PubMed ID: 15723656
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
[TBL] [Abstract][Full Text] [Related]
28. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
29. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
30. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
[TBL] [Abstract][Full Text] [Related]
31. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
Fang HT; Zhang B; Pan XF; Gao L; Zhen T; Zhao HX; Ma L; Xie J; Liu Z; Yu XJ; Cheng X; Feng TT; Zhang FX; Yang Y; Hu ZG; Sheng GQ; Chen YL; Chen SJ; Chen Z; Zhou GB
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2521-6. PubMed ID: 22308476
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
35. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
Kinsella P; Greene LM; Bright SA; Pollock JK; Butini S; Campiani G; Bauer S; Williams DC; Zisterer DM
Invest New Drugs; 2016 Apr; 34(2):159-67. PubMed ID: 26885657
[TBL] [Abstract][Full Text] [Related]
36. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
38. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
[TBL] [Abstract][Full Text] [Related]
39. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
